On May 20, 2021 CENE welcomed Rodney Rietze, PhD, Co-founder and CEO of iVexSol. The company has developed an advanced manufacturing process for lentiviral vectors, gene-editing reagents that are critical components in the manufacturing processes of cell and gene therapies (CGTs). 

Rod began his studies at the University of Calgary. Find out more about Rod's journey from the University of Calgary to iVexSol and manufacturing in Canada in this CENE program moderated by CENE Board Member Vinit Nijhawan, Managing Director, MassVentures.

For more information about upcoming CENE events, please visit thecene.org.